Cargando…

The versatile heparin in COVID‐19

Detalles Bibliográficos
Autor principal:	Thachil, Jecko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. 2020
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906146/ https://www.ncbi.nlm.nih.gov/pubmed/32239799 http://dx.doi.org/10.1111/jth.14821

Ejemplares similares

Differentiating biochemical from clinical heparin resistance in COVID-19
por: Lisman, Ton, et al.
Publicado: (2020)

Heparin – Messias or Verschlimmbesserung?
por: Swan, Dawn, et al.
Publicado: (2021)

Type and dose of heparin in Covid‐19: Reply
por: Thachil, Jecko, et al.
Publicado: (2020)

Clinical significance of measuring plasminogen activator inhibitor-1 in sepsis
por: Iba, Toshiaki, et al.
Publicado: (2017)

Lessons learnt from COVID‐19 coagulopathy
por: Thachil, Jecko
Publicado: (2021)

Hypoxia—An overlooked trigger for thrombosis in COVID‐19 and other critically ill patients
por: Thachil, Jecko
Publicado: (2020)

Thromboprophylaxis in COVID-19 – Rationale and considerations
por: Bristogiannis, Sotirios, et al.
Publicado: (2021)

A proposal for staging COVID‐19 coagulopathy
por: Thachil, Jecko, et al.
Publicado: (2020)

To escalate thromboprophylacic heparin intensity in COVID‐19 or not? That is still the question
por: Bikdeli, Behnood
Publicado: (2022)

Usefulness of Combining D-Dimers with Thromboelastography
por: Thachil, Jecko
Publicado: (2020)

Coagulation abnormalities and thrombosis in patients with COVID-19
por: Levi, Marcel, et al.
Publicado: (2020)

The implications of aspirin resistance in renal failure
por: Thachil, Jecko
Publicado: (2008)

Abnormal coagulation tests before kidney biopsies—what next?
por: Thachil, Jecko
Publicado: (2013)

The difficult distinction between haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura
por: Thachil, Jecko
Publicado: (2008)

Is it hyperfibrinolysis or fibrinolytic shutdown in severe COVID-19?
por: Nielsen, Nathan D., et al.
Publicado: (2022)

Proposal of the Definition for COVID-19-Associated Coagulopathy
por: Iba, Toshiaki, et al.
Publicado: (2021)

The application of anticoagulant therapy to sepsis
por: Thachil, Jecko, et al.
Publicado: (2017)

Approach to the Diagnosis and Classification of Blood Cell Disorders
por: Thachil, Jecko, et al.
Publicado: (2017)

The unique characteristics of COVID-19 coagulopathy
por: Iba, Toshiaki, et al.
Publicado: (2020)

Non‐factor therapies for bleeding disorders: A primer for the general haematologist
por: Swan, Dawn, et al.
Publicado: (2022)

Alpha the versatile: Guardians of the islets
por: Kawamori, Dan
Publicado: (2018)

DOACs and “newer” hemophilia therapies in COVID‐19: Reply
por: Thachil, Jecko, et al.
Publicado: (2020)

Commentary: Are platelet patterns repeated in delayed heparin-induced thrombocytopenia/heparin-induced thrombocytopenia and thrombosis syndrome after cardiac surgery?
por: Kramer, Robert S., et al.
Publicado: (2020)

ISTH interim guidance on recognition and management of coagulopathy in COVID‐19
por: Thachil, Jecko, et al.
Publicado: (2020)

Haematological Diseases in the Tropics
por: Thachil, Jecko, et al.
Publicado: (2014)

Bioengineered heparin: Is there a future for this form of the successful therapeutic?
por: Lord, Megan S, et al.
Publicado: (2014)

Versatile Quality Control Methods for Nanopore Sequencing
por: Bolognini, Davide, et al.
Publicado: (2019)

Practical management of the haemorrhagic complications of myeloproliferative neoplasms
por: Jones, Edward, et al.
Publicado: (2022)

Chronic anticoagulation is not associated with a reduced risk of acute kidney injury in hospitalised Covid-19 patients
por: Parker, Kathrine, et al.
Publicado: (2021)

Benefit, Necessity or Harm by Administering Heparin during Neurointerventional Procedures?
por: Berlis, Ansgar
Publicado: (2021)

Nebulised heparin: a new approach to the treatment of acute lung injury?
por: Suter, Peter M
Publicado: (2008)

Measuring the anticoagulant effect of low molecular weight heparins in the critically ill
por: Crowther, Mark, et al.
Publicado: (2006)

Fondaparinux in heparin‐induced thrombocytopenia: A decade's worth of clinical experience
por: Schindewolf, Marc
Publicado: (2018)

Anticoagulation in chronic kidney disease patients—the practical aspects
por: Hughes, Stephen, et al.
Publicado: (2014)

Rotational thromboelastometry in critically ill COVID‐19 patients does not predict thrombosis
por: Dujardin, Romein W. G., et al.
Publicado: (2022)

Heparin-induced thrombocytopenia during renal replacement therapy in the intensive care unit
por: Davenport, Andrew
Publicado: (2008)

A need for evidence-based clinical practice guidelines for the use of heparins in the elderly
por: Gouin-Thibault, Isabelle, et al.
Publicado: (2010)

Asymptomatic Joint Bleeding and Joint Health in Hemophilia: A Review of Variables, Methods, and Biomarkers
por: Gooding, Richard, et al.
Publicado: (2021)

UK prescribing practice of anticoagulants in patients with chronic kidney disease: a nephrology and haematology-based survey
por: Parker, Kathrine, et al.
Publicado: (2023)

Thromboembolism in nephrotic syndrome: controversies and uncertainties
por: Parker, Kathrine, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_08298q683sr6037rua16uh9j55